	US 12,286,668 B2
	SH2B adapter protein 3 for the prediction of bone marrow response and immune response
Gustav Steinhoff, Rethwisch (DE)
Assigned to UNIVERSITÄT ROSTOCK, Rostock (DE)
Appl. No. 16/603,981
Filed by UNIVERSITÄT ROSTOCK, Rostock (DE)
PCT Filed Apr. 10, 2018, PCT No. PCT/EP2018/059194 § 371(c)(1), (2) Date Oct. 9, 2019, PCT Pub. No. WO2018/189198, PCT Pub. Date Oct. 18, 2018.
Claims priority of application No. 10 2017 107 661.1 (DE), filed on Apr. 10, 2017.
Prior Publication US 2020/0115743 A1, Apr. 16, 2020
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6883 (2018.01); G06F 17/18 (2006.01)

CPC C12Q 1/6851 (2013.01) [C12Q 1/686 (2013.01); C12Q 1/6883 (2013.01); G06F 17/18 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)]

7 Claims

1. A method for treating a human subject in need of autologous intramyocardial CD133+purified bone marrow stem cell transplantation wherein the human subject's SH2B3 gene expression is lower than that of a non-responder, the method comprising:

i. sampling a tissue from the human subject to determine the human subject's tissue SH2B3 gene expression and sampling a tissue from a plurality of non-responders to determine the non-responder's SH2B3 gene expression, to determine that the SH2B3 gene expression in the subject's tissue is lower than the SH2B3 gene expression in the non-responder's tissue,

ii. treating the subject with autologous intramyocardial CD133+purified bone marrow stem cell transplantation.